Key result
Ivabradine slows ventricular response in a patient with ADHF and AFib, enabling rapid decongestion.
Why the study?
Pharmacologic rate control in patients with AF and rapid ventricular response with decreased cardiac function is challenging, and alternative therapies are needed.
Does ivabradine improve heart rate control in a patient with atrial fibrillation with rapid ventricular response and acute decompensated heart failure?
Case Report (n=1)
Does ivabradine improve heart rate control in a patient with atrial fibrillation with rapid ventricular response and acute decompensated heart failure?
Ivabradine may be a useful alternative for heart rate control in patients with atrial fibrillation with rapid ventricular response and depressed systolic function when standard therapies are contraindicated or ineffective.
May support ivabradine for rate control in select AF patients with ADHF when standard agents fail; hypothesis-generating case report requiring prospective trials.
BACKGROUND: Achieving pharmacologic rate control in patients with atrial fibrillation (AF) with rapid ventricular response (RVR) can be tricky when the patient's underlying cardiac function is decreased. We present a case illustrating how ivabradine can be useful in this clinical scenario. CASE SUMMARY: A 95-year-old woman with a history of systolic heart failure (HF) presented with acute decompensated HF in AF with RVR. Beta blockade and calcium channel blockade were avoided given her cardiac history, and diuresis with high doses of furosemide was ineffective. Her ventricular response slowed with ivabradine, allowing for rapid decongestion and a safe discharge home. DISCUSSION: current of cardiac pacemaker cells to slow heart rate (HR), and it currently carries a class IIa recommendation to reduce the risk of HF hospitalization and cardiac death in patients with left ventricular ejection fraction ≤35% and a symptomatic HR ≥70 b.p.m. Although current recommendations are for patients in sinus rhythm, ivabradine has a theoretical benefit in patients with AF given its mechanism of action. Because it does not negatively affect inotropy or blood pressure, ivabradine was used in our patient with a good clinical outcome. Our case provides an example of ivabradine's usefulness in patients with AF in RVR with a history of depressed systolic function.
No takes yet. Share an insight, caveat, or question.
Hardison et al. (2022) conducted a case report in Acute decompensated heart failure in atrial fibrillation with rapid ventricular response (n=1). Ivabradine was evaluated on Ventricular response slowing and decongestion. Ivabradine successfully slowed the ventricular response in a 95-year-old woman with acute decompensated heart failure and atrial fibrillation, allowing for rapid decongestion and safe discharge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: